Evidence map›Paper›PMID 39429516›Full record

ReviewOncoimmunology2024

Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.

Yan Wang, Liwei Zhao, Zhen Zhang, Peng Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yan WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Liwei ZhaoCentre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
Zhen ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Peng LiuCentre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.ORCID 0000-0002-1682-9222

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.

Indexed as

Immune Checkpoint InhibitorsNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenHumansImmunogenic Cell DeathImmunotherapyOxaliplatinB7-H1 AntigenImmune Checkpoint InhibitorsOxaliplatinPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCancer immunotherapyFc receptorImmune checkpoint inhibitorImmunogenic cell deathTotal neoadjuvant therapy

Identifiers

PMID39429516
PMCPMC11487966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.